# Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)

> **NCT01137968** · PHASE2 · COMPLETED · sponsor: **Geron Corporation** · enrollment: 116 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** imetelstat
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT01137968
- **Lead sponsor:** Geron Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2013-09
- **Final completion:** 2013-09
- **Target enrollment:** 116 (ACTUAL)
- **Last updated:** 2016-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01137968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01137968, "Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01137968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*